Attending JPM in San Francisco January 13 - 16, 2025? Learn about ZyVersa’s near-term milestones for Inflammasome Inhibitor IC 100 and Renal Cholesterol Efflux Mediator™ VAR 200 https://bit.ly/4fo5o9U
ZyVersa Therapeutics Inc.
制药业
Weston，FL 912 位关注者
Restoring Health, Transforming Lives Through Innovation
关于我们
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.
- 网站
-
http://www.zyversa.com
ZyVersa Therapeutics Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Weston，FL
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Drug Development、Orphan Disease、Nephrology和Immunology
地点
ZyVersa Therapeutics Inc.员工
-
Peter Wolfe
CFO Director Financial Planning and Analysis with P&L Management Expertise | Open to New Opportunities
-
Greg Freitag
Board Member: PDS Biotechnology Company (NASDAQ: PDSB) and ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA)
-
Karen Cashmere
Chief Commercial Officer at ZyVersa Therapeutics Inc.
-
Steve Glover
Co-Founder, Chairman, Chief Executive Officer at ZyVersa Therapeutics
动态
-
Attending JPM in San Francisco January 13 - 16, 2025? Learn about ZyVersa’s drug candidates for obesity with metabolic complications and for kidney diseases. https://bit.ly/4fo5o9U
-
-
Attending JPM in San Francisco January 13 - 16, 2025? Learn about ZyVersa’s Phase 2a Cholesterol Efflux Mediator™ VAR 200 for kidney disease. https://bit.ly/4fo5o9U
-
-
Attending JPM in San Francisco January 13 - 16, 2025? Learn about ZyVersa’s Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications. https://bit.ly/4fo5o9U
-
-
Learn what our CEO said about the potential of Inflammasome ASC Inhibitor IC 100 to control inflammation driving stroke-related cardiovascular injury: https://bit.ly/40Uiwjk
-
-
Following a stroke, Inflammasome ASC Inhibitor IC 100 attenuated inflammation in the heart and improved cardiac function in an animal model. Learn how: https://bit.ly/40Uiwjk
-
The mechanism underlying cardiac dysfunction following a stroke includes activation of AIM2 inflammasomes which trigger a systemic inflammatory response. Learn more: https://bit.ly/40Uiwjk
-
Learn what our CEO said about Inflammasome ASC Inhibitor IC 100’s MOA to control inflammation in obesity vs that of NLRP3 inhibitors: https://bit.ly/4fB9ITR
-
-
Learn about the IOC’s Consensus Statement on Obesity Care vs Weight Loss: https://lnkd.in/dX8cTk_c
-
-
Learn how inflammasome inhibition restores pancreatic beta cell function and improves metabolic status in obesity: https://bit.ly/4fB9ITR